State Street’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-884,374
| Closed | -$195M | – | 4280 |
|
|
2025
Q4 | $195M | Buy |
884,374
+111,615
| +14% | +$18M | 0.01% | 951 |
|
|
2025
Q3 | $74M | Buy |
772,759
+535,822
| +226% | +$34.2M | ﹤0.01% | 1526 |
|
|
2025
Q2 | $11.5M | Buy |
236,937
+214,361
| +950% | +$5.15M | ﹤0.01% | 2508 |
|
|
2025
Q1 | $486K | Buy |
22,576
+3,500
| +18% | +$77.7K | ﹤0.01% | 3594 |
|
|
2024
Q4 | $513K | Buy |
19,076
+5,500
| +41% | +$89.4K | ﹤0.01% | 3614 |
|
|
2024
Q3 | $146K | Hold |
13,576
| – | – | ﹤0.01% | 3894 |
|
|
2024
Q2 | $162K | Sell |
13,576
-1
| -0% | -$14 | ﹤0.01% | 3874 |
|
|
2024
Q1 | $250K | Sell |
13,577
-775
| -5% | -$11.1K | ﹤0.01% | 3823 |
|
|
2023
Q4 | $228K | Hold |
14,352
| – | – | ﹤0.01% | 3871 |
|
|
2023
Q3 | $270K | Buy |
14,352
+1,650
| +13% | +$32.4K | ﹤0.01% | 3846 |
|
|
2023
Q2 | $287K | Sell |
12,702
-1,060
| -8% | -$24.9K | ﹤0.01% | 3890 |
|
|
2023
Q1 | $350K | Buy |
13,762
+2,215
| +19% | +$62.9K | ﹤0.01% | 3873 |
|
|
2022
Q4 | $175K | Hold |
11,547
| – | – | ﹤0.01% | 4157 |
|
|
2022
Q3 | $145K | Buy |
11,547
+2,735
| +31% | +$37.8K | ﹤0.01% | 4281 |
|
|
2022
Q2 | $86K | Hold |
8,812
| – | – | ﹤0.01% | 4580 |
|
|
2022
Q1 | $147K | Buy |
8,812
+1,092
| +14% | +$18.5K | ﹤0.01% | 4498 |
|
|
2021
Q4 | $196K | Buy |
7,720
+4,070
| +112% | +$127K | ﹤0.01% | 4362 |
|
|
2021
Q3 | $164K | Hold |
3,650
| – | – | ﹤0.01% | 4423 |
|
|
2021
Q2 | $147K | Sell |
3,650
-29,286
| -89% | -$1.24M | ﹤0.01% | 4287 |
|
|
2021
Q1 | $1.75M | Buy |
32,936
+5,868
| +22% | +$290K | ﹤0.01% | 3489 |
|
|
2020
Q4 | $1.08M | Buy |
27,068
+3,736
| +16% | +$186K | ﹤0.01% | 3541 |
|
|
2020
Q3 | $1.33M | Buy |
23,332
+2,097
| +10% | +$148K | ﹤0.01% | 3350 |
|
|
2020
Q2 | $1.57M | Buy |
+21,235
| New | +$1.38M | ﹤0.01% | 3275 |
|
|
2017
Q2 | – | Sell |
-6,226
| Closed | -$970K | – | 3706 |
|
|
2017
Q1 | $970K | Buy |
6,226
+734
| +13% | +$129K | ﹤0.01% | 3273 |
|
|
2016
Q4 | $1.14M | Buy |
5,492
+907
| +20% | +$188K | ﹤0.01% | 3252 |
|
|
2016
Q3 | $1.05M | Buy |
4,585
+544
| +13% | +$126K | ﹤0.01% | 3182 |
|
|
2016
Q2 | $833K | Buy |
4,041
+2,167
| +116% | +$524K | ﹤0.01% | 3310 |
|
|
2016
Q1 | $475K | Buy |
1,874
+175
| +10% | +$40.3K | ﹤0.01% | 3360 |
|
|
2015
Q4 | $582K | Buy |
1,699
+195
| +13% | +$58.6K | ﹤0.01% | 3313 |
|
|
2015
Q3 | $383K | Buy |
1,504
+368
| +32% | +$105K | ﹤0.01% | 3378 |
|
|
2015
Q2 | $318K | Buy |
+1,136
| New | +$349K | ﹤0.01% | 3430 |
|
State Street's CDTX Position: Q1 2026 in Review
State Street sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 884,374 shares — an estimated $195M sold.
State Street first reported a position in CDTX in Q2 2015 and held it in 31 quarters. The position peaked at $195M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- State Street reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- State Street sold 884,374 Cidara Therapeutics shares in Q1 2026, an estimated $195M.
- State Street first reported a position in Cidara Therapeutics in Q2 2015 and held it in 31 quarters.
- State Street's Cidara Therapeutics position peaked at $195M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.